GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026

References are made to (i) the circular (the "**Circular**") and (ii) the notice (the "**Notice**") both dated April 17, 2026 issued by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**") in relation to the annual general meeting of the Company (the "**AGM**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

THE ANNUAL GENERAL MEETING

The Board is pleased to announce that the AGM was held at 10:00 a.m. on Monday, May 11, 2026 at GENFLEET Meeting Room, Building 73, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai, PRC.

As at the time of the AGM, the Company had a total of 370,366,630 Shares in issue, comprising 338,029,020 H Shares and 32,337,610 Unlisted Shares. Among these, none of the H Shares or Unlisted Shares was held as treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited), and no voting rights attached to the treasury Shares may be exercised at the AGM. The total number of Shares entitling the holders to attend and vote for or against all the resolutions in the Notice proposed at the AGM was 370,366,630. There were no repurchased Shares which are pending cancellation and accordingly should be excluded from the total number of issued Shares for the purposes of the AGM. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed for consideration and approval by the Shareholders at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholders were required to abstain from voting at the AGM under the Listing Rules and none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed for consideration and approval by the Shareholders at the AGM.

The AGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Listing Rules and the articles of association of the Company. All Directors, namely, Dr. Qiang LU, Dr. Jiong LAN, Ms. ZHANG Wei, Mr. ZHU Jingyang, Ms. TAO Sha, Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo, attended the AGM in person or by electronic means.

The Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

All the resolutions as set out in the Notice were put to vote by way of poll by the Shareholders (including their proxies and authorised representatives) at the AGM.

POLL RESULTS OF THE AGM

The poll results of the proposed resolutions (the "**Resolutions**") at the AGM were as follows:

ORDINARY RESOLUTIONS[1]		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the 2025 Report of the Board.	180,741,594 (99.942824%)	0 (0%)	103,400 (0.057176%)
2.	To consider and approve the 2025 Audited Consolidated Financial Statements.	180,741,594 (99.942824%)	0 (0%)	103,400 (0.057176%)
3.	To consider and approve the 2025 Annual Report.	180,741,594 (99.942824%)	0 (0%)	103,400 (0.057176%)
4.	To consider and review the 2025 and 2026 Directors' remuneration package.	180,741,594 (99.942824%)	0 (0%)	103,400 (0.057176%)
5.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for 2026, and to approve to authorise the Board to determine their remunerations and enter into the relevant agreements.	175,651,173 (97.128026%)	5,090,421 (2.814798%)	103,400 (0.057176%)
6.	To consider and approve the proposed amendments to the Working Rules for the Independent Non-executive Directors.	180,741,594 (99.942824%)	0 (0%)	103,400 (0.057176%)
7.	To consider and approve the proposed amendments to the Related Party Transaction Managements System.	180,740,074 (99.941983%)	1,520 (0.000840%)	103,400 (0.057176%)

SPECIAL RESOLUTIONS[1]		Number of votes (%)		
		For	Against	Abstain
8.	To consider and approve the proposed granting of the general mandate to the Board to repurchase H Shares.	180,740,093 (99.941994%)	0 (0%)	104,901 (0.058006%)
9.	To consider and approve the proposed granting of the general mandate to the Board to issue Shares and sale or transfer of treasury shares.	144,703,770 (80.015358%)	36,036,323 (19.926636%)	104,901 (0.058006%)
10.	To consider and approve the proposed amendments to the Rules of Procedure for the Shareholders' Meetings.	180,740,074 (99.941983%)	1,520 (0.000840%)	103,400 (0.057176%)
11.	To consider and approve the proposed amendments to the Rules of Procedure for the Board of Directors.	180,740,074 (99.941983%)	1,520 (0.000840%)	103,400 (0.057176%)

Note:

(1) Please refer to the Circular for the full text of the Resolutions. Ordinary resolutions shall be passed by votes representing more than one-half of the voting rights held by the Shareholders (including proxies thereof) attending the AGM. Special resolutions shall be passed by votes representing at least two-thirds of the voting rights held by the Shareholders (including proxies thereof) attending the AGM.

As more than one-half of the votes were cast in favour of ordinary resolutions no. 1 to 7, and two-thirds of the votes were cast in favour of special resolutions no. 8 to 11, all resolutions proposed at the AGM were duly passed by way of poll by the Shareholders.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, May 11, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive Directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive Directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive Directors.